WO2001003669A3 - Delivery of liposomal-encapsulated antioxidants and applications thereof - Google Patents

Delivery of liposomal-encapsulated antioxidants and applications thereof Download PDF

Info

Publication number
WO2001003669A3
WO2001003669A3 PCT/CA2000/000806 CA0000806W WO0103669A3 WO 2001003669 A3 WO2001003669 A3 WO 2001003669A3 CA 0000806 W CA0000806 W CA 0000806W WO 0103669 A3 WO0103669 A3 WO 0103669A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
liposomal
applications
antioxidants
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/000806
Other languages
French (fr)
Other versions
WO2001003669A2 (en
Inventor
Pang N Shek
Zacharias E Suntres
Jie Fan
Ori D Rotstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minister of National Defence of Canada
Original Assignee
Minister of National Defence of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minister of National Defence of Canada filed Critical Minister of National Defence of Canada
Priority to AU61427/00A priority Critical patent/AU6142700A/en
Priority to CA002340757A priority patent/CA2340757A1/en
Priority to EP00947706A priority patent/EP1133278A2/en
Priority to JP2001508950A priority patent/JP2003504322A/en
Publication of WO2001003669A2 publication Critical patent/WO2001003669A2/en
Publication of WO2001003669A3 publication Critical patent/WO2001003669A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A liposomal composition comprises a hydrophilic sulfhydryl agent and a lipophilic antioxidant, e.g., N-acetyl cysteine and/or α-tocopherol, and a method of delivery by contacting a pulmonary tissue of a mammal with the liposomal composition to achieve a prolonged antioxidant effect.
PCT/CA2000/000806 1999-07-07 2000-07-07 Delivery of liposomal-encapsulated antioxidants and applications thereof Ceased WO2001003669A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU61427/00A AU6142700A (en) 1999-07-07 2000-07-07 Delivery of liposomal-encapsulated antioxidants and applications thereof
CA002340757A CA2340757A1 (en) 1999-07-07 2000-07-07 Delivery of liposomal-encapsulated antioxidants and applications thereof
EP00947706A EP1133278A2 (en) 1999-07-07 2000-07-07 Delivery of liposomal-encapsulated antioxidants and applications thereof
JP2001508950A JP2003504322A (en) 1999-07-07 2000-07-07 Delivery of antioxidants encapsulated by liposomes and their application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14254599P 1999-07-07 1999-07-07
US60/142,545 1999-07-07

Publications (2)

Publication Number Publication Date
WO2001003669A2 WO2001003669A2 (en) 2001-01-18
WO2001003669A3 true WO2001003669A3 (en) 2001-07-12

Family

ID=22500256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000806 Ceased WO2001003669A2 (en) 1999-07-07 2000-07-07 Delivery of liposomal-encapsulated antioxidants and applications thereof

Country Status (5)

Country Link
EP (1) EP1133278A2 (en)
JP (1) JP2003504322A (en)
AU (1) AU6142700A (en)
CA (1) CA2340757A1 (en)
WO (1) WO2001003669A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
EP3015101B1 (en) 2005-10-03 2019-08-21 PINSKY, Mark A. Non-phospholipid liposomes comprising hyaluronic acid
WO2008089408A1 (en) * 2007-01-18 2008-07-24 Pinsky Mark A Materials and methods for delivering antioxidants into the skin
ES2710498T3 (en) 2007-12-26 2019-04-25 Mark A Pinsky Collagen formulations to improve skin care
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
JP2012521389A (en) * 2009-03-25 2012-09-13 ノバルティス アーゲー Pharmaceutical composition containing drug and siRNA
CN101829075B (en) * 2010-04-27 2011-07-20 中国人民解放军第三军医大学第一附属医院 Applications of kukoamine A and kukoamine B
WO2021203143A1 (en) * 2020-04-03 2021-10-07 Vivacelle Bio, Inc. Compositions and methods for treating or preventing multiple organ dysfunction syndrome
PH12022552818A1 (en) * 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
MX2024002736A (en) * 2024-03-01 2025-09-02 Juan Socorro Armendariz Borunda Compositions comprising acetylated derivatives of l-cysteine and 5-methyl-1-phenyl -2(1h)-pyridone in nanoparticles and uses thereof
CN119280164B (en) * 2024-10-16 2025-11-25 中国药科大学 A nano-formulation for treating ischemia-reperfusion injury, its preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013265A1 (en) * 1992-12-11 1994-06-23 Smith Milton G A free radical quenching liposomal composition
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013265A1 (en) * 1992-12-11 1994-06-23 Smith Milton G A free radical quenching liposomal composition
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 99, no. 25, 19 December 1983, Columbus, Ohio, US; abstract no. 206087m, L. KHAIRY ET AL.: "reversal of acetaminophen intoxication with an N-acetylcysteine-liposome preparation" page 68; column 1; XP002156058 *
RES. COMMUN. CHEM. PATHOL. PHARMACOL., vol. 42, no. 1, 1983, pages 157 - 160 *
See also references of EP1133278A2 *
T. MOTOYAMA ET AL.: "Synergistic inhibition of oxidation in dispersed phosphatidylcholine liposomes by a combination of vitamin E and cysteine", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 270, no. 2, 1 May 1989 (1989-05-01), New York (US), pages 655 - 661, XP002156057 *

Also Published As

Publication number Publication date
CA2340757A1 (en) 2001-01-18
EP1133278A2 (en) 2001-09-19
AU6142700A (en) 2001-01-30
JP2003504322A (en) 2003-02-04
WO2001003669A2 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
AU2001286578A1 (en) Topical antioxidant having vitamin c and method of combination with topical agent by user
ATE334663T1 (en) MEDICINAL COMPOSITION WITH DELAYED RELEASE
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
CA2379605A1 (en) Topical suspension formulations containing ciprofloxacin and dexamethasone
DK1112005T4 (en) Antioxidant composition comprising acetyl L-carnitine and alpha-lipoic acid
HUP0401604A3 (en) Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities and pharmaceutical compositions containing them
AU2001240753A1 (en) Lipid nanocapsules, preparation method and use as medicine
WO2002100437A3 (en) Ophthalmic compositions comprising hyaluronic acid
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
PT1089704E (en) TRICOLOGICAL LOCATION FOR TOPIC APPLICATION
AU1095901A (en) Tissue products containing antiviral agents which are mild to the skin
PT1121127E (en) PHARMACEUTICAL COMPOSITIONS ORAIS CONTAINING BUPRENORFIN
AU2001275677A1 (en) 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants
AU2001248215A1 (en) Cosmetically active composition
WO2004009038A3 (en) Cosmetic preparations with antibacterial properties comprising glycyrrhetinic acid
WO2002067886A3 (en) Skin composition
AU2001271266A1 (en) Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
BR0213536A (en) Ribavirin Syrup Formulations
AU2002221131A1 (en) Blood lipid ameliorant composition
AU2003254566A1 (en) Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
AU2003269871A1 (en) Radiosensitizer composition containing n-acetylphytosphingosine analogs and n,n-dimethyl-phytosphingosine analogs as the active ingredients
WO2004082612A3 (en) Liposomal formulations and methods of use
WO2003030862A3 (en) Anaesthetic compositions and method for their administration
AU2002339169A1 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
WO2001022917A8 (en) Effervescent compositions comprising nimesulide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2340757

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2340757

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000947706

Country of ref document: EP

Ref document number: 61427/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 508950

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09763131

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000947706

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000947706

Country of ref document: EP